ATE318328T1 - Diagnostika und therapeutika für osteoporose - Google Patents

Diagnostika und therapeutika für osteoporose

Info

Publication number
ATE318328T1
ATE318328T1 AT00961425T AT00961425T ATE318328T1 AT E318328 T1 ATE318328 T1 AT E318328T1 AT 00961425 T AT00961425 T AT 00961425T AT 00961425 T AT00961425 T AT 00961425T AT E318328 T1 ATE318328 T1 AT E318328T1
Authority
AT
Austria
Prior art keywords
osteoporosis
diagnostics
therapeutic products
therapeutic
products
Prior art date
Application number
AT00961425T
Other languages
German (de)
English (en)
Inventor
Dijk Simon Van
Gordon W Duff
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Application granted granted Critical
Publication of ATE318328T1 publication Critical patent/ATE318328T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00961425T 1999-08-30 2000-08-30 Diagnostika und therapeutika für osteoporose ATE318328T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15146099P 1999-08-30 1999-08-30

Publications (1)

Publication Number Publication Date
ATE318328T1 true ATE318328T1 (de) 2006-03-15

Family

ID=22538869

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961425T ATE318328T1 (de) 1999-08-30 2000-08-30 Diagnostika und therapeutika für osteoporose

Country Status (11)

Country Link
US (2) US6558905B1 (enExample)
EP (1) EP1212464B1 (enExample)
JP (1) JP2004504802A (enExample)
AT (1) ATE318328T1 (enExample)
AU (2) AU785040B2 (enExample)
BR (1) BR0014150A (enExample)
CA (1) CA2382848C (enExample)
DE (1) DE60026150T2 (enExample)
ES (1) ES2261239T3 (enExample)
MX (1) MXPA02002251A (enExample)
WO (1) WO2001016377A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147182A0 (en) * 1999-06-30 2002-08-14 Interleukin Genetics Inc Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplorype
US20090023147A1 (en) * 1999-08-30 2009-01-22 Kenneth Kornman Diagnostics and therapeutics for osteoporosis
WO2004065939A2 (en) * 2003-01-16 2004-08-05 Decode Genetics Ehf. Methods for diagnosing osteoporosis or a susceptibility to osteoporosis based on haplotype association
US20030152947A1 (en) * 2001-06-15 2003-08-14 Crossman David C. Methods for detecting and treating the early onset of aging-related conditions
US20070264645A1 (en) * 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
JP2005529585A (ja) * 2002-01-25 2005-10-06 インターリューキン ジェネティックス インコーポレイテッド Ｉｌ−１遺伝子群ならびに関連する炎症性多型およびハプロタイプ
WO2004018642A2 (en) * 2002-08-24 2004-03-04 Creighton University Methods for detecting genes associated with bone properties and/or height
CN1863928A (zh) * 2003-08-08 2006-11-15 英特利金遗传学有限公司 骨质疏松的诊断和治疗
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
RU2271827C1 (ru) * 2004-09-28 2006-03-20 Федеральное государственное учреждение"Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи Федерального агенства по здравоохранению и социальному развитию"(ФГУ "СПбНИИ ЛОР Росздрава") Способ определения тактики лечения рекомбинантным цитокином, регулирующим воспаление
US8590329B2 (en) 2004-12-22 2013-11-26 Johnson Controls Technology Company Medium voltage power controller
US7353662B2 (en) * 2004-12-22 2008-04-08 York International Corporation Medium voltage starter for a chiller unit
WO2007050794A2 (en) * 2005-10-25 2007-05-03 Interleuken Genetics, Inc. The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
ES2431671T3 (es) * 2006-11-15 2013-11-27 Interleukin Genetics, Inc. El complejo génico de IL-1 y resistencia a la insulina: polimorfismos asociados, haplotipos y métodos para usarlos
WO2017123696A1 (en) 2016-01-12 2017-07-20 Interleukin Genetics, Inc. Methods for predicting response to treatment
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
EP3980561A1 (en) 2019-06-06 2022-04-13 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
CA1316520C (en) 1987-05-19 1993-04-20 Larry C. Hamilton Valve
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
WO1993011149A1 (en) 1991-12-03 1993-06-10 Thomas Jefferson University Methods of detecting a genetic predisposition for osteoporosis
CA2141300C (en) 1992-07-31 2006-03-14 Nigel Alexander Morrison Assessment of vitamin d receptors allelic variation
EP0675903B1 (en) 1992-12-28 2004-09-29 David J Baylink Bone resorption assay
IL108947A0 (en) 1993-03-12 1994-06-24 Osteopharm Ltd Bone stimulating factor
CA2164498C (en) 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
GB9706359D0 (en) 1997-03-27 1997-05-14 Gemini International Holdings Polymorphisms of an il-1 receptor antagonist gene
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease

Also Published As

Publication number Publication date
AU785040B2 (en) 2006-08-31
MXPA02002251A (es) 2003-08-20
AU2006203097B2 (en) 2009-03-12
US20040110168A1 (en) 2004-06-10
EP1212464A2 (en) 2002-06-12
CA2382848C (en) 2011-01-04
DE60026150T2 (de) 2006-11-16
AU2006203097A1 (en) 2006-08-17
WO2001016377A2 (en) 2001-03-08
US6558905B1 (en) 2003-05-06
CA2382848A1 (en) 2001-03-08
BR0014150A (pt) 2002-05-14
AU7338000A (en) 2001-03-26
DE60026150D1 (de) 2006-04-27
WO2001016377A3 (en) 2002-01-17
ES2261239T3 (es) 2006-11-16
EP1212464B1 (en) 2006-02-22
JP2004504802A (ja) 2004-02-19

Similar Documents

Publication Publication Date Title
DE60026150D1 (de) Diagnostika und therapeutika für osteoporose
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
PT1446387E (pt) Derivados de aril-1,4-pirazina substituídos
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
DE69927823T2 (de) Hydrogel für die therapeutische behandlung von aneurysmas
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DE69937515D1 (de) Chirurgische Vorrichtung für die Hornhaut
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
TR200200278T2 (tr) Kalsilitik bileşimler
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
NO20005548L (no) Mykobakterieinhibitorer
WO2002072883A3 (de) Nukleotidträger zur diagnose und therapie oraler erkrankungen
NZ514691A (en) Method to type prion proteins
DE60039708D1 (de) Menschliches chordin und polynukleotiden die dafür kodieren
DE69936502D1 (de) Zeitregistriersystem für den Pflegesektor
DE59808637D1 (de) Vorrichtung für die behandlung von flüssigkeiten
DE59911136D1 (de) Pflegemittel für ärztliche bzw. zahnärztliche Instrumente
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
DK1332229T3 (da) Fremgangsmåde til screening af midler til at behandle overvægt
IT1280629B1 (it) Tripeptide per il trattamento delle forme cancerose, in particolare per il trattamento del melanoma.
UA42301A (uk) Засіб "камілаль" для лікування і профілактики проктологічних захворювань

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties